- Home
- IMCC vs DRMA Comparison
IMCC vs DRMA Comparison
Compare IMCC & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCC
- DRMA
- Stock Information
- Founded
- IMCC 1980
- DRMA 2014
- Country
- IMCC Israel
- DRMA United States
- Employees
- IMCC N/A
- DRMA N/A
- Industry
- IMCC Medicinal Chemicals and Botanical Products
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- IMCC Health Care
- DRMA Health Care
- Exchange
- IMCC Nasdaq
- DRMA Nasdaq
- Market Cap
- IMCC 5.3M
- DRMA 4.5M
- IPO Year
- IMCC N/A
- DRMA 2021
- Fundamental
- Price
- IMCC $2.65
- DRMA $0.60
- Analyst Decision
- IMCC
- DRMA Strong Buy
- Analyst Count
- IMCC 0
- DRMA 1
- Target Price
- IMCC N/A
- DRMA $3.00
- AVG Volume (30 Days)
- IMCC 465.6K
- DRMA 94.5K
- Earning Date
- IMCC 08-13-2025
- DRMA 08-06-2025
- Dividend Yield
- IMCC N/A
- DRMA N/A
- EPS Growth
- IMCC N/A
- DRMA N/A
- EPS
- IMCC N/A
- DRMA N/A
- Revenue
- IMCC $37,894,737.00
- DRMA N/A
- Revenue This Year
- IMCC $47.12
- DRMA N/A
- Revenue Next Year
- IMCC $12.83
- DRMA N/A
- P/E Ratio
- IMCC N/A
- DRMA N/A
- Revenue Growth
- IMCC 12.68
- DRMA N/A
- 52 Week Low
- IMCC $1.29
- DRMA $0.57
- 52 Week High
- IMCC $7.12
- DRMA $5.00
- Technical
- Relative Strength Index (RSI)
- IMCC 50.26
- DRMA 29.24
- Support Level
- IMCC $2.67
- DRMA $0.57
- Resistance Level
- IMCC $3.35
- DRMA $0.63
- Average True Range (ATR)
- IMCC 0.40
- DRMA 0.04
- MACD
- IMCC -0.05
- DRMA -0.01
- Stochastic Oscillator
- IMCC 33.94
- DRMA 11.55
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.